Meeting
2022 ASCO Annual Meeting
Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer.
Authors
Michael Lattanzi
Memorial Sloan Kettering Cancer Center, New York, NY
Michael Lattanzi , Alexander Solovyov , Jayon Lihm , Colleen Quinlan , Karissa Whiting , Hao Li , Hikmat A. Al-Ahmadie , Min Yuen Teo , David Henry Aggen , Irina Ostrovnaya , Ashley Marie Regazzi , Marwah Jihad , Dean F. Bajorin , Arjun Vasant Balar , Amir Mortazavi , Taha Merghoub , Gopa Iyer , Jonathan E. Rosenberg , Benjamin Greenbaum , Samuel Aaron Funt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT02989584
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4584)
DOI
10.1200/JCO.2022.40.16_suppl.4584
Abstract #
4584
Poster Bd #
75
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial.
First Author: Samuel Aaron Funt
Poster
2022 ASCO Genitourinary Cancers Symposium
Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.
First Author: Shilpa Gupta
Poster
2019 ASCO Annual Meeting
A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC).
First Author: Samuel Aaron Funt
Poster
2020 Genitourinary Cancers Symposium
Development of a composite biomarker-based calculator to predict the probability of pathologic complete response (pT0) after neoadjuvant pembrolizumab (pembro) in muscle invasive bladder cancer (MIBC).
First Author: Andrea Necchi